Causes of the first AIDS‐defining illness and subsequent survival before and after the advent of combined antiretroviral therapy *

To analyse the impact of combined antiretroviral treatment (cART) on survival with AIDS, according to the nature of the first AIDS‐defining clinical illness (ADI); to examine trends in AIDS‐defining causes (ADC) and non‐AIDS‐defining causes (non‐ADC) of death.

[1]  Gitte Pedersen,et al.  Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.

[2]  Melissa R Pfeiffer,et al.  Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City , 2006, Annals of Internal Medicine.

[3]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[4]  Santiago Pérez-Hoyos,et al.  Trends in AIDS and Mortality in HIV-Infected Subjects With Hemophilia From 1985 to 2003: The Competing Risks for Death Between AIDS and Liver Disease , 2006, Journal of acquired immune deficiency syndromes.

[5]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[6]  Mark R Wallace,et al.  Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.

[7]  R. Greenblatt,et al.  Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984–2004 , 2005, AIDS.

[8]  M. Gill,et al.  Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003 , 2005, HIV medicine.

[9]  D. Costagliola,et al.  Causes et caractéristiques des décès des patients infectés par le VIH-1, en succès immuno-virologique sous traitement antirétroviral , 2004 .

[10]  P. Morlat,et al.  Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.

[11]  F. Lert,et al.  Comment vit-on en France avec le VIH/sida ? , 2004, Population & Sociétés.

[12]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[13]  N. Low,et al.  Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival , 2003, AIDS.

[14]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[15]  S. Chevret,et al.  Improving estimates of event incidence over time in populations exposed to other events: application to three large databases. , 2003, Journal of clinical epidemiology.

[16]  O. Kirk,et al.  Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy , 2002, Annals of Internal Medicine.

[17]  Mary Young,et al.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. , 2002, The American journal of medicine.

[18]  B. Gallagher,et al.  Survival Rates in NYC in the Era of Combination ART , 2002, Journal of acquired immune deficiency syndromes.

[19]  J. Kaldor,et al.  Impact of Highly Active Antiretroviral Therapy on Individual AIDS‐Defining Illness Incidence and Survival in Australia , 2002, Journal of acquired immune deficiency syndromes.

[20]  D. Costagliola,et al.  Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  C. Katlama,et al.  Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. , 2001, Blood.

[22]  R. Selik,et al.  Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. , 2001, JAMA.

[23]  B. Gazzard,et al.  The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. , 2001, The Journal of infection.

[24]  A. Mocroft,et al.  Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. , 2001, The New England journal of medicine.

[25]  P. Pezzotti,et al.  Differential Impact of Combined Antiretroviral Therapy on the Survival of Italian Patients With Specific AIDS‐Defining Illnesses , 2000, Journal of acquired immune deficiency syndromes.

[26]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[27]  D Costagliola,et al.  Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine. , 2000, International journal of epidemiology.

[28]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[29]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[30]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[31]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[32]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[33]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[34]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[35]  A. Mocroft,et al.  Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. , 1997, International journal of epidemiology.

[36]  A. Phillips,et al.  Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. , 1996, Journal of clinical epidemiology.

[37]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[38]  P. Morlat,et al.  [Causes and characteristics of death among HIV-1 infected patients with immunovirologic response to antiretroviral treatment]. , 2004, Presse medicale.

[39]  A. Mocroft,et al.  Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy , 2001 .